

Lewens Labs



Introduction

- Established in 2014 by Mr. Moksha Udani in Gujarat, India
- Engaged in manufacturing of Active Pharmaceutical Ingredients with a focus on small volume products API manufacturing Company incorporated in 2014.
- Initiated 20 KL manufacturing capacity plant in 2018 with first expansion in 2021-22 which increased the capacity to 45 KL
- Present across therapeutic segments catering a wide range of Customers in India and now expanding globally
- Largest manufacturer of products such as : Silodosin and Ivabradine commanding 90% market share in India

Lewens Snapshot: Growth + Execution + Delivery

- Years Completed^ 6 Years : Young Company with Global Vision. Factory incepted in 2018
- C A G R 40 % : Rapidly growing topline by adding products and increasing market presentation
- Exclusive Projects : 3 Product tie up for early launches with key formulators of India
- Customer Acquisition : 50 Marquee customers of India on board and multiple projects added with 80% of them
- Brands Relaunched : Only API supplier in India which led to relaunch of 2 brands
- Geographies catered : (10+) Increasing presence and touching customers across territories

Vision & How Shall We Achieve it?

Trusted API Partner

Emerge as a preferred partner to companies by delivering right quality products with efficient timelines

Product Selection

Focus on mid value to high value products and achieving best in industry costs by innovative chemistry and novel routes

Global & Focused


Catering to EU/Korea/Japan and ROW; US Business focused on intermediates only

CMO Partner

With global approvals in place – We plan to spare partial capacity for working with innovators for intermediates development and supply

X Factor

Coming together of all the efforts across teams and led by a young entrepreneur who has built the business from grounds up with honesty and resilience embedded in the organization



Differentiating Strengths: A blend of ideation and execution

Agility

- Developed and commands leading market share in 3 key products in India: Silodosin, Ivabradine and Rosuvastatin Calcium which was dominated by large established players earlier
- Strong R&D team focused on turnaround of projects is a span of 3-6 months
- Achieved high asset utilization ratio owing to product selection and market penetration

Transparency

- Promoters and Board of Directors are well known figures in Industry with a reputation of utmost honesty and transparency
- Lewens Labs track record of transparency and reliability has helped bag strategic products from top pharmaceutical companies for development and supply

Focus

- An unflinching focus on processes and improvements along with compliance of cGMP norms has led to working with multiple customers in a short span of time
- End to end solution with backward integration was executed where required
- A belief that our partner should win has been the driving factor of our strategy and has played a pivotal role in identifying and catering to niche opportunities for them and us

Regulatory Pathway

- State GMP : Site Compliant and Certification available since 2018
- WHO GMP : Site Compliant and Certification available since 2018
- EU GMP : Application submitted for inspection to Authority
- CEP's : 1st product CEP awaited in Q2 2024 and 3 others in pipeline

Your Partner For Growth




Early identification with a strong pipeline of early launches


Key Launches and Developments




To launch Orbifloxacin



To launch Apremilast



To launch Iguratimod



To launch Fimasartan

New Product Pipeline



Resmetirom has the potential to be the first medication approved for patients with NASH. The MAESTRO-NAFLD-1 study provides clinicians with important information about the safety profile and key noninvasive measures of efficacy.



Thank You